Pharmacopsychiatry 2003; 36: 130-135
DOI: 10.1055/s-2003-43054
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Cholesterol, a Modulator of Membrane-associated Aβ-fibrillogenesis

J. McLaurin1 , A. A. Darabie1 , M. R. Morrison1
  • 1Centre for Research in Neurodegenerative Diseases and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
Further Information

Publication History

Publication Date:
22 October 2003 (online)

One of the major pathological features of Alzheimer’s disease is the presence of extracellular amyloid plaques that are predominantly composed of the amyloid-β peptide (Aβ). Characterisation of plaques demonstrated the predominance of two peptides differing at the carboxyl terminus by 2 hydrophobic amino acids, Aβ40 and Aβ42. Diffuse plaques associated with AD are composed predominantly of Aβ42, whereas senile plaques contain both Aβ40 and Aβ42. Recently, it has been suggested that diffuse plaque formation is initiated as a plasma membrane bound Aβ species and that Aβ42 is the critical component. In order to investigate this hypothesis, we have examined Aβ40/42-lipid interactions using in situ atomic force microscopy, electron microscopy and fluorescence anisotropy. While the association of Aβ42 with planar bilayers resulted in peptide aggregation but no fibre formation, this was not the case for Aβ40 where we observed preferential fibre formation. Cholesterol, a key membrane component and modulating factor in AD, is inversely correlated with the extent of Aβ40/42-bilayer interaction. These results were confirmed using fluorescence anisotropy to evaluate the effect of Aβ on membrane fluidity and fluorimetry to confirm membrane integrity. Our results suggest that the enhanced amyloidogenic properties of Aβ42 are not correlated with fibril formation but aggregation on bilayer surfaces.

References

  • 1 Avdulov N A, Chochina S V, Igbavboa U, O,Hare E O, Schroeder F, Cleary J P, Wood W G. Lipid binding to amyloid beta-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids.  J Neurochemistry. 1997;  69 1746-1752
  • 2 Bayerl T M, Bloom M. Physical properties of single phospholipid bilayers adsorbed to micro glass beads. A new vesicular model system studied by 2H-nuclear magnetic resonance.  Biophys J. 1990;  58 357-362
  • 3 Bodovitz S, Klein W L. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein.  J Biol Chem. 1996;  271 4436-4440
  • 4 Brian A A, McConnell H M. Allogeneic stimulation of cytotoxic T cells by supported planar membranes.  Proc Natl Acad Sci USA. 1984;  81 6159-6163
  • 5 DePlanque M RR, Greathouse D V, Koeppe R E, Schafer H, Marsh D, Killian J A. Influence of lipid/peptide hydrophobic mismatch on the thickness of diacylphosphatidylcholine bilayers. A 2H NMR and ESR study using designed transmembrane α-helical peptides and gramicidin A.  Biochemistry. 1998;  37 9333-9345
  • 6 Galbete J L, Rodriguez-Martin T, Peressini E, Modena P, Bianchi R, Forloni G. Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway.  Biochem J. 2000;  348 307-313
  • 7 Gimpl G, Burger K, Fahrenholz F. Cholesterol as modulator of receptor function.  Biochemistry. 1997;  36 10 959-10 974
  • 8 Groves J T, Ulman N, Boxer S G. Micropatterning fluid lipid bilayers on solid supports.  Science. 1997;  275 651-653
  • 9 Hertel C, Terzi E, Hauser N, Jakob-Rotne R, Seelig J, Kemp J A. Inhibition of the electrostatic interaction between beta-amyloid peptide and membranes prevents beta-amyloid-induced toxicity.  Proc Natl Acad Sci. 1997;  94 9412-9416
  • 10 Howland D S, Trusko S P, Savage M J, Reaume A G, Lang D M, Hirsch J D,. et al . Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol.  J Biol Chem. 1998;  273 16 576-16 582
  • 11 Janshoff A, Bong D T, Steinem C, Johnson J E, and Ghadiri M R. An animal virus-derived peptide switches membrane morphology: possible relevance to Nodaviral transfection processes.  Biochemistry. 1999;  38 5328-5336
  • 12 Kawahara M, Kuroda Y, Arispe N, Rojas E. Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line.  J Biol Chem. 2000;  275 14 077-14 083
  • 13 Kilsdonk E PC, Yancey P G, Stoudt G W, Bangerter F W, Johnson W J. Cellular cholesterol efflux mediated by cyclodextrins.  J Biol Chem. 1995;  270 17 250-17 256
  • 14 McLaurin J, Franklin T, Chakrabartty A, Fraser P E. Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest.  J Mol Biol. 1998;  278 183-194
  • 15 McLaurin J, Franklin T, Fraser P E, Chakrabartty A. Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides.  J Biol Chem. 1997;  273 4506-4515
  • 16 McLaurin J, Yang D, Yip C M, Fraser P E. Modulating Factors in Aβ Fibril Formation.  J Struct Biol. 2000;  130 259-270
  • 17 Mizuno T, Nakata M, Naiki H, Michikawa M, Wang R, Haass C, Yanagisawa K. Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture.  J Biol Chem. 1999;  274 15 110-15 114
  • 18 Mou J, Czaijkowsky D M, and Shao Z. Gramicidin A aggregation in supported gel state phosphatidylcholine bilayers.  Biochemistry. 1996;  35 3222-3226
  • 19 Pillot T, Drouet B, Queille S, Labeur C, Vandekerchkhove J, Rosseneu M. et al . Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer,s disease.  J Neurochem. 1999;  73 1626-1634
  • 20 Racchi M, Baetta R, Salvietti N, Ianna P, Franceschini G, Paoletti R. et al . Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content.  Biochem J. 1997;  322 893-898
  • 21 Refolo L M, Pappolla M A, Malester B, LaFrancois J, Bryant-Thomas T, Wang R ,. et al . Hypercholesterolemia accelerates the Alzheimer,s amyloid pathology in a transgenic mouse model.  Neurobiol Disease. 2000;  7 321-331
  • 22 Roher A E, Kuo Y -M, Kokjohn K M, Emmerling M R, Gracon S. Amyloid and lipids in the pathology of Alzheimer disease.  Amyloid: Int J Exp Clin Inves. 1999;  6 136-145
  • 23 Salafsky J, Groves J T, Boxer S G. Architecture and function of membrane proteins in planar supported bilayers: a study with photosynthetic reaction centers.  Biochemistry. 1996;  35 14 773-14 781
  • 24 Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N. et al . Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer,s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.  Nat Med. 1996;  2 864-870
  • 25 Selkoe D J. Alzheimer,s disease: genotypes, phenotypes, and treatments.  Science. 1997;  275 630-631
  • 26 Simons M, Keller P, DeStrooper B, Beyreuther K, Dotti C G, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons.  Proc Natl Acad Sci USA. 1998;  95 6460-6464
  • 27 Sparks D L, Scheff S W, Hunsaker J C, Liu H, Landers T, Gross D R. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol.  Exp Neurol. 1994;  126 88-94
  • 28 St. George-Hyslop P. Molecular Genetics of Alzheimer,s Disease.  Biol Psychiatry. 2000;  47 183-199
  • 29 Terzi E, Holzemann G, Seelig J. Alzheimer beta-amyloid peptide 25 - 35: electrostatic interactions with phospholipid membranes.  Biochemistry. 1994;  33 7434-441
  • 30 Terzi E, Holzemann G, Seelig J. Self-association of beta-amyloid peptide (1 - 40) in solution and binding to lipid membranes.  J Mol Biol. 1995;  252 633-642
  • 31 Van Blitterswijk W J, VanHoeven R P, Van der Meer B W. Lipid structural order parameters (reciprocal of fluidity) in biomembranes derived from steady-state fluorescence polarization measurements.  Biochim Biophys Acta. 1981;  644 323-332
  • 32 Webster S Rogers J. Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation.  J Neurosci Res. 1996;  4 58-66
  • 33 Wood W G, Schroeder F, Avdulov N A, Chochina S V, Igbavboa U. Recent advances in brain cholesterol dynamics: transport, domains, and Alzheimer's disease.  Lipids. 1999;  34 225-234
  • 34 Yamaguchi H, Maat-Schieman M LC, Duinen S G, Prins F A, Neeskens P, Natte R, Roos R AC. Amyloid beta protein (Abeta) starts to deposit as plasma membrane-bound form in diffuse plaques of brains from hereditary cerebral hemorrhage with amyloidosis-Dutch type, Alzheimer disease and nondemented aged subjects.  J Neuropathol Exp Neurol. 2000;  59 723-732
  • 35 Yip C M, McLaurin J. Amyloid-β Peptide Assembly: A Critical Step in Fibrillogenesis and Membrane Disruption.  Biophys J. 2000;  80 1359-1371

Dr. JoAnne McLaurin

Centre for Research in Neurodegenerative Diseases

Tanz Neuroscience Building

Queen’s Park Crescent West

Toronto

Ontario

Canada

M5S 3H2

Phone: (416) 978-1035

Fax: (416) 978-1878

Email: j.mclaurin@utoronto.ca

    >